CN116083326A - Preparation containing bacillus coagulans metaplasium, preparation method thereof and application thereof in preparation of weight-losing and lipid-lowering drugs - Google Patents
Preparation containing bacillus coagulans metaplasium, preparation method thereof and application thereof in preparation of weight-losing and lipid-lowering drugs Download PDFInfo
- Publication number
- CN116083326A CN116083326A CN202310312991.6A CN202310312991A CN116083326A CN 116083326 A CN116083326 A CN 116083326A CN 202310312991 A CN202310312991 A CN 202310312991A CN 116083326 A CN116083326 A CN 116083326A
- Authority
- CN
- China
- Prior art keywords
- bacillus coagulans
- mice
- preparation
- preparation containing
- metazoan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/02—Separating microorganisms from their culture media
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/06—Lysis of microorganisms
- C12N1/066—Lysis of microorganisms by physical methods
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/07—Bacillus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A preparation containing bacillus coagulans metaplasias, a preparation method thereof and application thereof in preparing weight-losing and lipid-lowering medicaments relate to the field of food microorganisms. Inoculating bacillus coagulans JA845 into a liquid glucose LB culture medium, and centrifuging to discard supernatant after shake cultivation; preparing bacterial suspension by bacterial precipitation; centrifuging the bacterial suspension, removing the supernatant, and adding sterile purified water for resuspension; carrying out ultrasonic wall breaking treatment and vacuum freeze drying on the re-suspension bacteria liquid to obtain metapowder; the metagen powder is dissolved in normal saline to prepare the bacillus coagulans JA845 metagen suspension. The Bacillus coagulans JA845 metazoan has a certain regulation and control effect on the weight of obese mice, can effectively improve the glucose intolerance condition of the mice, improve the content of short chain fatty acids in the intestinal tracts of the mice, increase the richness and community diversity of intestinal flora of the mice, improve beneficial bacteria in the intestinal tracts of the mice, and reduce the abundance of harmful bacteria.
Description
Technical Field
The invention relates to the technical field of food microorganisms, in particular to a preparation containing bacillus coagulans metaplasias, a preparation method thereof and application thereof in preparing weight-losing and lipid-lowering medicines.
Background
In recent years, the incidence of obesity and metabolic diseases has increased, and these diseases have a great negative impact on human health and socioeconomic development. Studies have shown that dysregulation of intestinal flora may be one of the important causes of these diseases. Thus, prevention and treatment of these diseases by improving intestinal flora is a hotspot of research.
Many studies now suggest that obesity and metabolic diseases can be positively influenced by modulating the intestinal flora. Probiotics are microorganisms beneficial to the human body and can colonise and proliferate in the intestinal tract. The probiotics can promote the balance of normal microbial flora in intestinal tracts, and increase the production of Short Chain Fatty Acids (SCFAs). SCFA are an energy source that promote intestinal motility and normal intestinal mucosal cell growth and repair, while also reducing cholesterol and blood glucose levels. Thus, increasing SCFA production may reduce the risk of obesity and metabolic diseases.
The metazoan is the metabolite component of the probiotics after the probiotics are processed and is generally called as including thalli and metabolites. The study proves that the screened metazoan has the immunity enhancing capability superior to that of the original viable bacteria, and has high physiological activity even though being treated by high-temperature action or gastrointestinal digestive juice. Compared with traditional active probiotics, the metazoan has no activity but retains a large amount of nutrition and effective components such as vitamins, lipids, proteins, polypeptides, organic acids, thallus components and the like. Thus, improving intestinal flora, increasing SCFA production by probiotics and/or metazoans may be an effective method for preventing and treating obesity. The research in the field provides a new thought and method for preventing and treating obesity, thereby being hopeful to improve the health condition of human beings and promoting the sustainable development of society.
Disclosure of Invention
The invention aims to provide a preparation containing bacillus coagulans metaplasias, a preparation method thereof and application thereof in preparing weight-losing and lipid-lowering medicines.
The technical scheme adopted by the invention for solving the technical problems is as follows:
the preparation method of the preparation containing the bacillus coagulans metaplasias comprises the following steps:
inoculating bacillus coagulans (Bacillus coagulans) JA845 into a liquid glucose LB culture medium, and centrifuging after shaking culture to discard the supernatant; preparing the obtained bacterial precipitate into bacterial suspension; centrifuging the obtained bacterial suspension, removing the supernatant, and adding sterile purified water for resuspension; performing ultrasonic wall breaking treatment on the obtained resuspended bacteria liquid in ice bath, and performing vacuum freeze drying on the liquid obtained by ultrasonic treatment to obtain bacillus coagulans (Bacillus coagulans) JA845 metapowder; the metagen powder is dissolved in physiological saline to prepare bacillus coagulans (Bacillus coagulans) JA845 metagen suspension.
As a preferred embodiment, the Bacillus coagulans (Bacillus coagulans) JA845 has been deposited at China general microbiological culture Collection center, with accession number: CGMCC No.19576.
As a preferred embodiment, bacillus coagulans (Bacillus coagulans) JA845 is inoculated in a liquid LB culture medium, cultured for 8-12 hours at 45-55 ℃ by shaking table 150-210 rpm, centrifuged for 8-12 minutes at 2700r/min-3300r/min and 2-6 ℃, and the supernatant is discarded to obtain bacterial precipitate.
As a preferred embodiment, the resulting bacterial pellet is formulated as a Bacillus coagulans (Bacillus coagulans) JA845 bacterial suspension with sterile physiological saline.
As a preferred embodiment, the bacterial suspension has a bacterial count of 8×10 9 CFU/mL。
As a preferred embodiment, the resulting bacterial suspension is centrifuged at 2700r/min-3300r/min at 2-6deg.C for 8-12 min, the supernatant is discarded, and sterile purified water is added for resuspension.
As a preferred embodiment, the parameters of the ultrasonic wall breaking treatment are as follows: 15min,800W.
As a preferred embodiment, the parameters of the vacuum freeze-drying are: pre-freezing at-40deg.C for 24 hr; the thickness of the frozen material is 2cm; the vacuum degree of the drying chamber is 10Pa; lyophilization time was 36h.
The preparation containing the bacillus coagulans metaplasium is prepared by the preparation method of the invention.
The invention relates to application of a preparation containing bacillus coagulans metaplasias in preparation of a weight-losing and lipid-lowering medicament.
The beneficial effects of the invention are as follows:
inoculating bacillus coagulans (Bacillus coagulans) JA845 into a liquid LB culture medium, and centrifuging to discard supernatant after shaking culture; preparing the obtained bacterial precipitate into bacterial suspension; centrifuging the obtained bacterial suspension, removing the supernatant, and adding sterile purified water for resuspension; performing ultrasonic wall breaking treatment on the obtained resuspended bacteria liquid in ice bath, and performing vacuum freeze drying on the liquid obtained by ultrasonic treatment to obtain bacillus coagulans (Bacillus coagulans) JA845 metapowder; the metagen powder is dissolved in physiological saline to prepare bacillus coagulans (Bacillus coagulans) JA845 metagen suspension. The obtained bacillus coagulans (Bacillus coagulans) JA845 metazoan has a certain regulation and control effect on the weight of obese mice, and compared with bacillus coagulans (Bacillus coagulans) JA845, the bacillus coagulans can more effectively improve the glucose intolerance condition of the mice and is more beneficial to improving the short chain fatty acid content in the intestinal tracts of the mice; meanwhile, after the metaplasia of the JA845 of the gastric lavage bacillus coagulans (Bacillus coagulans), the richness and community diversity of the intestinal flora of the mice are obviously increased, the beneficial bacteria in the intestinal tract of the mice are increased, the abundance of harmful bacteria is reduced, and the metaplasia of the JA845 of the bacillus coagulans (Bacillus coagulans) plays a role in regulating the balance of the intestinal flora. In conclusion, the bacillus coagulans (Bacillus coagulans) JA845 metaplasia prepared by the invention can be applied to the preparation of medicines with the functions of losing weight and reducing blood fat, and provides an effective method for preventing and/or treating obesity.
Drawings
FIG. 1 shows the effect of Bacillus coagulans (Bacillus coagulans) JA 845/Bacillus coagulans (Bacillus coagulans) JA845 metazoan on mouse body weight in example 2.
FIG. 2 shows liver oil red O-stained sections (A: blank; C: model; E: probiotic; G: metazoan) and epididymal hematoxylin-eosin-stained sections (B: blank; D: model; F: probiotic; H: metazoan) of each of the test groups in example 2.
FIG. 3 is the effect of Bacillus coagulans (Bacillus coagulans) JA 845/Bacillus coagulans (Bacillus coagulans) JA845 metazoan on oral glucose tolerance in obese mice (FIG. 3A) and the effect of the area under the blood glucose curve (FIG. 3B) in example 2.
FIG. 4 is the effect of Bacillus coagulans (Bacillus coagulans) JA 845/Bacillus coagulans (Bacillus coagulans) JA845 metazoan on intestinal flora in obese mice in example 2. In the figure, A is the analysis of alpha diversity of intestinal flora; b is PCA cluster analysis of intestinal flora; c is the analysis of the genus in the intestinal tract; d is the analysis of the heat map of the intestinal flora bacteria.
Detailed Description
The technical solutions of the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention, and it is apparent that the described embodiments are only some embodiments of the present invention, not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
The experimental methods in the following examples are conventional methods unless otherwise specified. The test materials used in the examples described below, unless otherwise specified, were purchased from conventional biochemical reagent stores. The quantitative tests in the following examples were all set up in triplicate and the results averaged.
Solid LB medium: the solvent is water, 10g/L of tryptone, 5g/L of yeast extract powder, 10g/L of sodium chloride and 15g/L of agar; ph=7.0 unless otherwise specified. Liquid LB medium differs from solid LB medium only in that no agar is added to the liquid LB medium.
SPF-grade healthy male C57BL/6J mice purchased from vinca Yisi laboratory animal technologies Co., ltd., production license number: SCXK (gei) -2011-0004. The animals are fed adaptively for one week, the temperature of the animal house is 21+/-2 ℃, the relative humidity is (40+/-10)%, and feeding and drinking are carried out freely.
Basal feed: purchased from vinca Yiss laboratory animal technology, inc.
High fat feed (% stands for g/100 g): 75% of basic feed, 10% of lard, 10% of yolk powder and 5% of cholesterol (food grade, purchased from Zhengzhou Xanthium chemical products Co., ltd.).
Bacillus coagulans (Bacillus coagulans) JA845 is preserved in China general microbiological culture Collection center, CGMCC, at the address: the collection number of Beijing, the Korean yang district, north Chen Xili No.1, 3 (China academy of sciences microbiological institute) is: CGMCC No.19576. In addition, other information about bacillus coagulans (Bacillus coagulans) JA845 includes isolation, identification, preservation, etc. all refer to chinese patent publication No. CN111518720a (the invention name is a strain of bacillus coagulans (Bacillus coagulans) JA845 and its application).
Example 1 preparation of a preparation containing Bacillus coagulans (Bacillus coagulans) metazoan
(1) Preparation of Bacillus coagulans (Bacillus coagulans) JA845 bacterial suspension
Inoculating Bacillus coagulans (Bacillus coagulans) JA845 into liquid glucose LB culture medium (glucose 10g/L, tryptone 10g/L, yeast extract 5g/L, sodium chloride 10g/L, pH of the culture medium is regulated to 7.4 by NaOH), culturing at a shaking table of 50 ℃ for 10 hours at 180rpm, centrifuging at 3000r/min and 4 ℃ for 10 minutes, and discarding the supernatant to obtain bacterial precipitate; preparing bacterial suspension of Bacillus coagulans (Bacillus coagulans) JA845 by aseptic physiological saline, and adjusting bacterial count of bacterial suspension to 8×10 according to OD600 absorbance and plate count result 9 CFU/mL。
(2) Preparation of Bacillus coagulans (Bacillus coagulans) JA845 metazoan
Taking 50mL of the bacillus coagulans (Bacillus coagulans) JA845 bacterial suspension, centrifuging at 3000r/min and 4 ℃ for 10min, discarding the supernatant, and adding 50mL of sterile purified water for resuspension to obtain a resuspension bacterial solution; using an ultrasonic breaker to carry out ultrasonic wall breaking on the heavy suspension fungus liquid in an ice bath, and carrying out ultrasonic conditions: 15min,800W; vacuum freeze-drying the liquid after ultrasonic wall breaking (pre-freezing temperature-40 ℃ C., pre-freezing time 24h, frozen material thickness 2cm, drying chamber vacuum degree 10Pa, freeze-drying time 36 h) to obtain bacillus coagulans (Bacillus coagulans) JA845 metapowder; the metapowder was dissolved in 50mL of physiological saline to prepare a bacillus coagulans (Bacillus coagulans) JA845 metasuspension, which was used for the subsequent animal experiments.
Example 2 influence of Bacillus coagulans (Bacillus coagulans) JA845 metazoan on lipid metabolism in liver and liver injury
(1) Packet processing
80 SPF-class healthy male C57BL/6J mice were subjected to adaptive feeding for one week, and feeding and drinking were freely performed by the mice. Then, random grouping was performed, and the groups were divided into 4 groups of 20, and the processing was as follows:
blank group: basal feed was given at weeks 2-8, and drinking water was freely ingested. The body weight was weighed weekly by pouring normal saline (single administration amount is 0.2 mL) once daily at 9-16 weeks, an oral glucose tolerance test was performed on the day of the end of the test, and then the test animals were sacrificed to take liver tissue, epididymal adipose tissue, and feces.
Model group: the high-fat feed is given in the 2-16 weeks, 5% fructose is free to drink water, and the weight gain is 20% higher than the average value of the normal blank group, so that the molding is successful. The body weight was weighed weekly by pouring normal saline (single administration amount is 0.2 mL) once daily at 9-16 weeks, an oral glucose tolerance test was performed on the day of the end of the test, and then the test animals were sacrificed to take liver tissue, epididymal adipose tissue, and feces.
Probiotic group: the high-fat feed is given in the 2-16 weeks, 5% fructose is free to drink water, and the weight gain is 20% higher than the average value of the normal blank group, so that the molding is successful. The Bacillus coagulans (Bacillus coagulans) JA845 bacterial suspension obtained in example 1 (single administration amount of 0.2 mL) was infused once daily for 9-16 weeks, the body weight was weighed weekly, an oral glucose tolerance test was performed on the day of the end of the test, and then the test animals were sacrificed to take liver tissue, epididymal adipose tissue, and feces.
The metatuple: the high-fat feed is given in the 2-16 weeks, 5% fructose is free to drink water, and the weight gain is 20% higher than the average value of the normal blank group, so that the molding is successful. The Bacillus coagulans (Bacillus coagulans) JA845 metaplastic suspension obtained in example 1 was infused once daily at 9-16 weeks (single administration amount was 0.2 mL), the body weight was weighed weekly, an oral glucose tolerance test was performed on the day of the end of the test, and then the test animals were sacrificed to take liver tissue, epididymal adipose tissue and feces.
Oral glucose tolerance test: after the last gastric lavage, the fasting is not forbidden for 12 hours, the blood glucose values of the mice are measured at five time points of 0min, 30min, 60min, 90min and 120min respectively by the gastric lavage glucose solution (the dosage is 2g/kg each), and the area under the blood glucose curve (area under the curve, AUC) is calculated according to the following formula.
AUC (mmol·h/L) =1/2 (g0+g30) ×30+1/2 (g30+g60) ×30+1/2 (g60+g90) ×30+1/2 (g90+g120) ×30; wherein: g0 to G120 are the blood glucose value/(mmol/L) of the mice in 0 to 120min respectively; 30 represents measurement interval time/(min).
(2) Relevant physiological and biochemical index detection
1. Mouse body weight detection
The initial body weight of the mice was approximately 19g-21g, with no significant difference. After 8 weeks of high-fat high-sugar feeding, the weight of the mice changed significantly, the weight of the mice was about 28.5g-29g, the weight of the mice in the blank group was about 22g-22.5g, and the weight of the mice fed with high-fat high-sugar was increased by more than 20% compared with that in the blank group, which indicates that the model was successful, as shown in fig. 1. The mice with gastric lavage of probiotics or metazoans started at week 8, the weight of the obese mice with the probiotic group and metazoans started at week ninth, the average weight of the mice in the model group reached 31.58g after the end of the experiment at week 16, and the average weights of the mice with healthy group, probiotic group and metazoans were 25.4g, 26.16g and 26.27g. This indicates that both bacillus coagulans (Bacillus coagulans) JA845 and bacillus coagulans (Bacillus coagulans) JA845 metazoans have a certain regulatory effect on the body weight of obese mice.
2. Oral glucose tolerance assessment in mice
As shown in the graph A of FIG. 2, the blood sugar values of all groups of mice are in normal values for 0min, after the gastric glucose solution is filled, the blood sugar values of all four groups of mice reach a peak value at 30min, the blood sugar value of the mice in the probiotics group is 14.83mmol/L, the blood sugar value of the mice in the metazoan group is 14.18mmol/L, and the blood sugar value of the mice in the model group is 18.1mmol/L; the blood sugar values of the four groups of mice fall back rapidly at the position of 30min-60min, and the blood sugar value is flat at the position of 90 min. The blood glucose values of the mice in the model group are always obviously higher than those of the mice in the other three groups in the period of 30min to 120min, but the blood glucose values of the mice in each group are all in a descending trend. As can be seen from FIG. 2B, the area under the curves of the probiotic group and the metatuple is significantly reduced compared with the model group, with a very significant difference (P < 0.01). The experimental data show that comparing the probiotic group with the metazoan group, the metazoan of the bacillus coagulans (Bacillus coagulans) JA845 is found to be more effective than the metazoan of the bacillus coagulans (Bacillus coagulans) JA845 in improving glucose intolerance of mice.
3. Effects on liver tissue and epididymal adipose tissue
Oil red O staining can specifically stain neutral fats such as triglycerides in tissues to red. As shown in fig. 3 (A, C, E, G), the pathological observation of oil red O staining of liver tissue of each group of mice shows that liver cells and liver lobules of the mice in the blank group have clear and complete structures and no lipid infiltration; the liver lipid infiltration phenomenon of mice in the model group is serious, and the neutral fat is densely distributed; compared with a model group, the probiotics group and the metagenome reduce the phenomena of lipid and infiltration to a certain extent, and the neutral fat distribution density is obviously reduced.
In examining epididymal adipose tissue, a blank (fig. 3B) observed a regular adipocyte structure and size; whereas the adipocytes of the model set (fig. 3D) were the largest and the cell walls the thinnest; the probiotic group (fig. 3F) inhibited the increase of adipocytes to some extent; the most obvious effect was in the metatuple (fig. 3H), showing that adipocyte size was close to normal.
6. Regulatory effect on intestinal flora in obese mice
The Chao 1 index reflects the abundance of communities in the sample, the greater the index, the more abundant the species; the Shannon index reflects the diversity of the community, the greater the Shannon index, the greater the diversity of the community. As can be seen from fig. 4 a, model group mice had a lower Chao 1 index than the blank group, and the difference was very significant (P < 0.01); the metazoan Chao 1 index and Shannon index are both higher than the model group, and the difference is significant (P < 0.05), which indicates that the richness and community diversity of the intestinal flora of the mice are obviously increased after metazoan of JA845 by the Bacillus coagulans (Bacillus coagulans).
The results of principal coordinate analysis (PCoA) analysis of the inter-group differences are shown in fig. 4B, from which the inter-group microbial community differences can be more intuitively observed. The blank group and the model group are far apart and clustered independently, which indicates that the two groups have large difference in microbial community structure. The probiotics group is highly overlapped with the metagenome, which shows that the bacillus coagulans (Bacillus coagulans) JA845 and the bacillus coagulans (Bacillus coagulans) JA845 metagenome have similar effect on the change of intestinal microflora, and the intestinal microflora has smaller difference; meanwhile, the metazoan group is intersected with the blank group, which shows that after the metazoan intervention of bacillus coagulans (Bacillus coagulans) JA845, the intestinal microbiota structure of the obese mice is more close to the blank group.
The levels of intestinal flora of each group of mice were analyzed and the results of the analysis are shown in fig. 4C and D. Post-biotics intervention with bacillus coagulans (Bacillus coagulans) JA845 and bacillus coagulans (Bacillus coagulans) JA845 was followed to test changes in microbial abundance in the mice intestinal flora. The abundance of Muribaculaceae and Lactobacillus in the intestinal tract of the mice in the model group is reduced compared with that of the mice in the blank group, the probiotics group and the metazoan group, and the abundance of harmful microorganisms such as Faecalibaculum and Vibrio desulphus (Desulfobibrio) is increased. Muribaculaceae and Lactobacillus (Lactobacillus) in intestinal tract can metabolize to produce short chain fatty acid, thereby increasing nutrient absorption and improving metabolism abnormality; the metabolism of faecalibaculom, devulcanization of vibrio (devulcanization) to produce harmful substances such as hydrogen sulfide, results in a weakening of the intestinal barrier and thus activates the inflammatory response. The beneficial bacteria in the intestinal tracts of mice with the probiotics group and the metagenome are increased, the abundance of harmful bacteria is reduced, and the effect of adjusting the balance of intestinal flora is fully demonstrated by the metagenome of the bacillus coagulans (Bacillus coagulans) JA 845.
6. Effect on short chain fatty acid content in intestinal tract
Short chain fatty acids in the intestinal tract have beneficial effects of inhibiting growth of harmful microorganisms in the intestinal tract, anti-inflammatory, and increasing satiety. The short chain fatty acid content in the intestinal tract of each group of mice is shown in table 1. The content of acetic acid, propionic acid, isobutyric acid, butyric acid, isovaleric acid and valeric acid in the feces of obese mice is obviously lower than that in the normal group. Compared with the model group, the content of acetic acid, propionic acid, isobutyric acid, butyric acid, isovaleric acid and valeric acid in the feces of the mice of the probiotics group and the metagenome is obviously increased (p < 0.01). And comparing short chain fatty acid in the feces of the probiotic group and the metatuple, wherein the contents of acetic acid, propionic acid, isobutyric acid, butyric acid and valeric acid of the metatuple are higher than those of the probiotic group. These results indicate that bacillus coagulans (Bacillus coagulans) JA845 metazoans are more beneficial to increasing short chain fatty acid content in the intestinal tract of obese mice than bacillus coagulans (Bacillus coagulans) JA 845.
TABLE 1 short chain fatty acid content in the faeces of mice of each group
| Grouping | Acetic acid (μg/g) | Propionic acid (μg/g) | Isobutyric acid (μg/g) | Butyric acid (μg/g) | Isovaleric acid (μg/g) | Valeric acid (μg/g) |
| Health group | 583.37±49.04 | 599.07±40.71 | 59.91±8.75 | 210.73±32.88 | 43.22±4.35 | 57.37±4.45 |
| Model group | 385.96±21.73 | 204.01±14.61 | 30.48±5.32 | 140.16±54.04 | 22.25±3.59 | 24.11±3.25 |
| Probiotics group | 503.07±54.14** | 249.89±20.29** | 46.31±0.29** | 224.73±13.33** | 38.98±1.83** | 48.76±8.23** |
| Metatuple | 558.97±33.38** | 336.23±36.16** | 48.71±5.53** | 338.30±66.73** | 35.94±5.46** | 63.83±6.52** |
The foregoing is merely a preferred embodiment of the present invention and it should be noted that modifications and adaptations to those skilled in the art may be made without departing from the principles of the present invention, which are intended to be comprehended within the scope of the present invention.
Claims (10)
1. A method for preparing a preparation containing bacillus coagulans metaplasias, comprising the steps of:
inoculating Bacillus coagulans JA845 to liquid glucose LB culture medium, shaking culture, centrifuging, and discarding supernatant; preparing the obtained bacterial precipitate into bacterial suspension; centrifuging the obtained bacterial suspension, removing the supernatant, and adding sterile purified water for resuspension; performing ultrasonic wall breaking treatment on the obtained resuspended bacteria liquid in ice bath, and performing vacuum freeze drying on the liquid obtained by ultrasonic treatment to obtain bacillus coagulans (JA 845 metapowder; the metagen powder is dissolved in physiological saline to prepare bacillus coagulans (Bacillus coagulans) JA845 metagen suspension.
2. The method for preparing a preparation containing Bacillus coagulans metazoan according to claim 1, wherein the Bacillus coagulans JA845 has been deposited in China general microbiological culture Collection center, with a deposit number of: CGMCC No.19576.
3. The method for preparing a preparation containing Bacillus coagulans metaplasias claimed in claim 1, wherein Bacillus coagulans JA845 is inoculated in a liquid LB medium, cultured for 8h-12h at 45-55deg.C shaking table 150rpm-210rpm, centrifuged for 8min-12min at 2700r/min-3300r/min at 2-6deg.C, and the supernatant is discarded to obtain bacterial pellet.
4. The method for producing a preparation containing a Bacillus coagulans metazoan according to claim 1, wherein the obtained bacterial pellet is prepared into a Bacillus coagulans (Bacillus coagulans) JA845 bacterial suspension with sterile physiological saline.
5. The method for producing a preparation containing Bacillus coagulans metazoan according to claim 1, wherein the bacterial count of the bacterial suspension is 8X 10 9 CFU/mL。
6. The method for preparing a preparation containing Bacillus coagulans metazoan according to claim 1, wherein the obtained bacterial suspension is centrifuged at 2700r/min-3300r/min at 2-6deg.C for 8-12 min, the supernatant is discarded, and sterile purified water is added for resuspension.
7. The method for preparing the preparation containing the bacillus coagulans metazoan according to claim 1, wherein the parameters of the ultrasonic wall breaking treatment are as follows: 15min,800W.
8. The method for preparing a preparation containing Bacillus coagulans metazoan according to claim 1, wherein the parameters of the vacuum freeze-drying are as follows: pre-freezing at-40deg.C for 24 hr; the thickness of the frozen material is 2cm; the vacuum degree of the drying chamber is 10Pa; lyophilization time was 36h.
9. The preparation of a preparation containing Bacillus coagulans metaplasium prepared by the method according to any one of claims 1 to 8.
10. The use of a preparation containing a Bacillus coagulans metazoan according to claim 9 for the preparation of a weight-reducing and lipid-lowering medicament.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310312991.6A CN116083326A (en) | 2023-03-28 | 2023-03-28 | Preparation containing bacillus coagulans metaplasium, preparation method thereof and application thereof in preparation of weight-losing and lipid-lowering drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310312991.6A CN116083326A (en) | 2023-03-28 | 2023-03-28 | Preparation containing bacillus coagulans metaplasium, preparation method thereof and application thereof in preparation of weight-losing and lipid-lowering drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116083326A true CN116083326A (en) | 2023-05-09 |
Family
ID=86199462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310312991.6A Pending CN116083326A (en) | 2023-03-28 | 2023-03-28 | Preparation containing bacillus coagulans metaplasium, preparation method thereof and application thereof in preparation of weight-losing and lipid-lowering drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116083326A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117838736A (en) * | 2024-01-29 | 2024-04-09 | 吉林省农业科学院(中国农业科技东北创新中心) | Application of bacillus coagulans JA845 in preparation of medicines for preventing and/or treating atherosclerosis |
| CN117899125A (en) * | 2024-01-19 | 2024-04-19 | 吉林省农业科学院(中国农业科技东北创新中心) | A preparation for preventing and/or treating hyperglycemia |
-
2023
- 2023-03-28 CN CN202310312991.6A patent/CN116083326A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117899125A (en) * | 2024-01-19 | 2024-04-19 | 吉林省农业科学院(中国农业科技东北创新中心) | A preparation for preventing and/or treating hyperglycemia |
| CN117838736A (en) * | 2024-01-29 | 2024-04-09 | 吉林省农业科学院(中国农业科技东北创新中心) | Application of bacillus coagulans JA845 in preparation of medicines for preventing and/or treating atherosclerosis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116083326A (en) | Preparation containing bacillus coagulans metaplasium, preparation method thereof and application thereof in preparation of weight-losing and lipid-lowering drugs | |
| CN110141585A (en) | A kind of composite probiotics ferment microbial inoculum and preparation method thereof for adjusting intestinal flora | |
| CN109125525B (en) | Composition for preventing and treating cardiovascular diseases and preparation method and application thereof | |
| CN112586744B (en) | Probiotic tablet capable of controlling weight and preparation method thereof | |
| CN111011856A (en) | Composition for relieving gastropathy, preparation method thereof and food for relieving gastropathy | |
| CN113943681B (en) | Bifidobacterium longum capable of reducing inflammatory reaction and relieving constipation | |
| CN103893215A (en) | Application of lactobacillus casei grx12 in preparation of product for treating chronic alcoholic liver injury | |
| CN110917174A (en) | Oral probiotic capsule for regulating balance of female vaginal flora and preparation method thereof | |
| CN116286551B (en) | Application of bifidobacterium longum subspecies infantis in regulating in-vivo fat metabolism, shaping, reducing fat and improving obesity | |
| LU502579B1 (en) | Bifidobacterium lactis for relieving constipation and application thereof | |
| CN111919890A (en) | Formula milk powder for middle-aged and old people for improving immunity and reducing blood sugar and blood fat and preparation method thereof | |
| CN114774315B (en) | Application of lactobacillus rhamnosus strain LRa05 in preparation of immunity enhancing product and/or eczema relieving product | |
| CN115120695A (en) | Licorice probiotic compound preparation CLPP-9 and application thereof in preventing or treating non-alcoholic fatty liver disease | |
| CN117264829A (en) | Lactobacillus plantarum for preventing and treating hypercholesterolemia, fermented product and application thereof | |
| CN110200186B (en) | Probiotic solid beverage and preparation method thereof | |
| JP2018532380A (en) | Enterobacteriaceae butyric acid intestini and uses thereof | |
| CN114703105A (en) | Application of composite probiotics in reducing blood fat or relieving obesity | |
| Zhang et al. | Chimonanthus nitens Oliv polysaccharides modulate immunity and gut microbiota in immunocompromised mice | |
| CN115992059B (en) | Lactobacillus johnsonii for producing feruloyl esterase and application thereof in relieving ulcerative colitis | |
| CN111406928B (en) | Red date fermented food with function of improving chronic diarrhea and preparation method and application thereof | |
| CN117838736B (en) | Application of bacillus coagulans JA845 in preparation of medicines for preventing and/or treating atherosclerosis | |
| KR101012672B1 (en) | The feed additive containing the mixed extractions of Coptidis Rhizoma, Lonicerae Flos and Mori Folium herbal mixture as an antibiotic and its manufacturing process | |
| KR102202092B1 (en) | Weissella koreensis nd824 strain having improved productivity of ornithine and composition comprisingng the same | |
| CN117899125A (en) | A preparation for preventing and/or treating hyperglycemia | |
| CN114874954B (en) | Lactobacillus curvatus capable of promoting production of short chain fatty acid in intestinal tract and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |